Show simple item record

dc.contributor.authorUeland, Thor
dc.contributor.authorSørvoll, Ingvild Hausberg
dc.contributor.authorMørtberg, Trude Victoria
dc.contributor.authorDahl, Tuva Børresdatter
dc.contributor.authorLerum, Tøri Vigeland
dc.contributor.authorMichelsen, Annika Elisabet
dc.contributor.authorRanheim, Trine
dc.contributor.authorNezvalova-Henriksen, Katerina
dc.contributor.authorDyrhol-Riise, Anne Ma
dc.contributor.authorHolme, Pål Andre
dc.contributor.authorAaløkken, Trond Mogens
dc.contributor.authorSkjønsberg, Ole Henning
dc.contributor.authorBarratt-Due, Andreas
dc.contributor.authorAhlen, Maria Therese
dc.contributor.authorAukrust, Pål
dc.contributor.authorHalvorsen, Bente
dc.date.accessioned2022-09-14T06:51:24Z
dc.date.available2022-09-14T06:51:24Z
dc.date.issued2022-02-28
dc.description.abstractThromboembolic events are frequent and associated with poor outcome in severe COVID-19 disease. Anti-PF4/polyanion antibodies are related to heparin-induced thrombocytopenia (HIT) and thrombus formation, but data on these antibodies in unselected COVID-19 populations are scarce. We assessed the presence of anti-PF4/polyanion antibodies in prospectively collected serum from an unselected cohort of hospitalized COVID-19 patients and evaluated if elevated levels could give prognostic information on ICU admission and respiratory failure (RF), were associated with markers of inflammation, endothelial activation, platelet activation, coagulation and fibrosis and were associated with long-term pulmonary CT changes. Five out of 65 patients had anti-PF4/polyanion reactivity with OD ≥0.200. These patients had more severe disease as reflected by ICU admission without any evidence of HIT. They also had signs of enhanced inflammation and fibrinogenesis as reflected by elevated ferritin and osteopontin, respectively, during the first 10 days of hospitalization. Increased ferritin and osteopontin persisted in these patients at 3 months follow-up, concomitant with pulmonary CT pathology. Our finding shows that the presence of anti-PF4/polyanion antibodies in unselected hospitalized COVID−19 patients was not related to HIT, but was associated with disease severity, inflammation, and pulmonary pathology after 3 months.en_US
dc.identifier.citationUeland, Sørvoll, Mørtberg, Dahl, Lerum, Michelsen, Ranheim, Nezvalova-Henriksen, Dyrhol-Riise, Holme, Aaløkken, Skjønsberg, Barratt-Due, Ahlen, Aukrust, Halvorsen. Anti-PF4/polyanion antibodies in COVID-19 patients are associated with disease severity and pulmonary pathology. Platelets. 2022;33(4):640-644en_US
dc.identifier.cristinIDFRIDAID 2028539
dc.identifier.doi10.1080/09537104.2022.2042238
dc.identifier.issn0953-7104
dc.identifier.issn1369-1635
dc.identifier.urihttps://hdl.handle.net/10037/26788
dc.language.isoengen_US
dc.publisherTaylor & Francisen_US
dc.relation.journalPlatelets
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2022 The Author(s)en_US
dc.titleAnti-PF4/polyanion antibodies in COVID-19 patients are associated with disease severity and pulmonary pathologyen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record